ATE468332T1 - Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin- - yi)aminderivate - Google Patents

Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin- - yi)aminderivate

Info

Publication number: ATE468332T1
Authority: AT; Austria
Prior art keywords: phenyl; pyrazole; pyrimidine; amine derivatives; derivatives
Prior art date: 2002-07-09

Application number

AT03762663T

Other languages

English (en)

Inventor

Pascal Furet

Patricia Imbach

Timothy Ramsey

Achim Schlapbach

Dieter Scholz

Giorgio Caravatti

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-07-09

Filing date

2003-07-08

Publication date

2010-06-15

2003-07-08 Application filed by Novartis Ag filed Critical Novartis Ag

2010-06-15 Application granted granted Critical

2010-06-15 Publication of ATE468332T1 publication Critical patent/ATE468332T1/de

Links

150000001412 amines Chemical class 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
GHIDSWLDHRXNQM-UHFFFAOYSA-N n-phenyl-4-(5-phenyl-1h-pyrazol-4-yl)pyrimidin-2-amine Chemical class N=1C=CC(C=2C(=NNC=2)C=2C=CC=CC=2)=NC=1NC1=CC=CC=C1 GHIDSWLDHRXNQM-UHFFFAOYSA-N 0.000 abstract 1
230000002062 proliferating effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT03762663T 2002-07-09 2003-07-08 Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin- - yi)aminderivate ATE468332T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0215844.2A GB0215844D0 (en)	2002-07-09	2002-07-09	Organic compounds
PCT/EP2003/007350 WO2004005282A1 (en)	2002-07-09	2003-07-08	PHENYL-[4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES

Publications (1)

Publication Number	Publication Date
ATE468332T1 true ATE468332T1 (de)	2010-06-15

Family

ID=9940097

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03762663T ATE468332T1 (de)	2002-07-09	2003-07-08	Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin- - yi)aminderivate

Country Status (13)

Country	Link
US (1)	US7691855B2 (de)
EP (1)	EP1521749B8 (de)
JP (1)	JP4478016B2 (de)
CN (1)	CN1330643C (de)
AT (1)	ATE468332T1 (de)
AU (1)	AU2003249993A1 (de)
BR (1)	BR0312573A (de)
CA (1)	CA2491635A1 (de)
DE (1)	DE60332629D1 (de)
ES (1)	ES2346427T3 (de)
GB (1)	GB0215844D0 (de)
PT (1)	PT1521749E (de)
WO (1)	WO2004005282A1 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE407132T1 (de) *	2000-12-05	2008-09-15	Vertex Pharma	Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen
AR039241A1 (es)	2002-04-04	2005-02-16	Biogen Inc	Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
US7154002B1 (en)	2002-10-08	2006-12-26	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US7250514B1 (en)	2002-10-21	2007-07-31	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US7381825B2 (en)	2003-03-17	2008-06-03	Takeda San Diego, Inc.	Histone deacetylase inhibitors
GB0311274D0 (en)	2003-05-16	2003-06-18	Astrazeneca Ab	Chemical compounds
NZ592039A (en)	2003-08-27	2013-03-28	Ophthotech Corp	Combination therapy for the treatment of ocular neovascular disorders
MXPA06007820A (es) *	2004-01-09	2006-09-01	Novartis Ag	Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina como inhibidores de igf-ir.
TW200528101A (en) *	2004-02-03	2005-09-01	Astrazeneca Ab	Chemical compounds
JP2008515986A (ja) *	2004-10-13	2008-05-15	ワイス	Ｎ−ベンゼンスルホニル置換アニリノ−ピリミジン類似物
WO2006050076A1 (en)	2004-10-29	2006-05-11	Janssen Pharmaceutica, N.V.	Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
JO2596B1 (en) *	2004-11-30	2011-02-27	نوفارتيس ايه جي	Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
EP1824831A2 (de)	2004-12-16	2007-08-29	Takeda San Diego, Inc.	Histondeacetylase-inhibitoren
EP1896436A2 (de)	2005-05-11	2008-03-12	Takeda San Diego, Inc.	Inhibitoren der histondeacetylase
EA200800321A1 (ru)	2005-07-14	2008-06-30	Такеда Сан Диего, Инк.	Ингибиторы гистондеацетилазы
JP4278172B2 (ja) *	2005-07-30	2009-06-10	アストラゼネカアクチボラグ	増殖性疾患の治療において使用するためのイミダゾリル−ピリミジン化合物
AR056556A1 (es)	2005-09-30	2007-10-10	Astrazeneca Ab	Imidazo(1,2-a)piridina con actividad antiproliferacion celular
SG10202003901UA (en)	2005-12-13	2020-05-28	Incyte Holdings Corp	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
WO2007105058A2 (en) *	2006-03-16	2007-09-20	Pfizer Products Inc.	Pyrazole compounds
CN103739595A (zh)	2006-10-02	2014-04-23	Irm责任有限公司	作为蛋白激酶抑制剂的化合物和组合物
EP2134175A4 (de) *	2007-03-29	2012-01-11	Glaxosmithkline Llc	Hemmer von akt-aktivität
KR20150036210A (ko)	2007-06-13	2015-04-07	인사이트 코포레이션	야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
JP2010533147A (ja) *	2007-07-13	2010-10-21	アデックスファルマエス．エイ．	代謝調節型グルタミン酸レセプターのモジュレーターとしてのピラゾール誘導体
WO2009016460A2 (en) *	2007-08-01	2009-02-05	Pfizer Inc.	Pyrazole compounds and their use as raf inhibitors
UA104849C2 (uk)	2007-11-16	2014-03-25	Інсайт Корпорейшн	4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus
CA2707989A1 (en)	2007-12-07	2009-06-11	Novartis Ag	Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
HUE030912T2 (en)	2008-02-15	2017-06-28	Rigel Pharmaceuticals Inc	Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
WO2010099139A2 (en)	2009-02-25	2010-09-02	Osi Pharmaceuticals, Inc.	Combination anti-cancer therapy
WO2010099364A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099363A1 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
SI2432472T1 (sl) *	2009-05-22	2019-11-29	Incyte Holdings Corp	3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
AR076794A1 (es)	2009-05-22	2011-07-06	Incyte Corp	Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
JP2012528175A (ja) *	2009-05-27	2012-11-12	アボット・ラボラトリーズ	キナーゼ活性のピリミジン阻害剤
TW201113285A (en)	2009-09-01	2011-04-16	Incyte Corp	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP2308866A1 (de) *	2009-10-09	2011-04-13	Bayer CropScience AG	Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
EP3354652B1 (de)	2010-03-10	2020-05-06	Incyte Holdings Corporation	Piperidin-4-yl azetidin-derivate als jak1-inhibitoren
PE20130216A1 (es)	2010-05-21	2013-02-27	Incyte Corp	Formulacion topica para un inhibidor de jak
ES2577829T3 (es)	2010-06-04	2016-07-19	F. Hoffmann-La Roche Ag	Derivados de aminopirimidina como moduladores de la LRRK2
NO2638031T3 (de)	2010-11-10	2018-03-10
US9034884B2 (en)	2010-11-19	2015-05-19	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
PE20140146A1 (es)	2010-11-19	2014-02-06	Incyte Corp	Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US9382229B2 (en)	2011-02-15	2016-07-05	The Johns Hopkins University	Compounds and methods of use thereof for treating neurodegenerative disorders
WO2012149014A1 (en)	2011-04-25	2012-11-01	OSI Pharmaceuticals, LLC	Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
CN103797010B (zh)	2011-06-20	2016-02-24	因塞特控股公司	作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
WO2013071232A1 (en) *	2011-11-11	2013-05-16	Beta Cat Pharmaceuticals, Llc	Compositions and methods for inhibition of tbl-1 binding to disease-associated molecules
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
TW201406761A (zh)	2012-05-18	2014-02-16	Incyte Corp	做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
PH12020551186B1 (en)	2012-11-15	2024-03-20	Incyte Holdings Corp	Sustained-release dosage forms of ruxolitinib
NZ746607A (en)	2012-11-21	2019-11-29	Ptc Therapeutics Inc	Substituted reverse pyrimidine bmi-1 inhibitors
RS62867B1 (sr)	2013-03-06	2022-02-28	Incyte Holdings Corp	Postupci i intermedijeri za dobijanje inhibitora jak
DK4374873T3 (da)	2013-07-12	2025-11-03	Astellas Us Llc	Middel til brug ved behandling eller forebyggelse af oftalmologiske tilstande
SMT202000315T1 (it)	2013-08-07	2020-07-08	Incyte Corp	Forme di dosaggio a rilascio prolungato per un inibitore di jak1
EA034866B1 (ru)	2013-08-30	2020-03-31	ПиТиСи ТЕРАПЬЮТИКС, ИНК.	Замещенные пиримидиновые ингибиторы bmi-1
WO2015076800A1 (en)	2013-11-21	2015-05-28	Ptc Therapeutics, Inc.	Substituted pyridine and pyrazine bmi-1 inhibitors
US9498467B2 (en)	2014-05-30	2016-11-22	Incyte Corporation	Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US10376511B2 (en) *	2015-08-04	2019-08-13	Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.	Pyrazole pyrimidine derivative and uses thereof
WO2019113487A1 (en)	2017-12-08	2019-06-13	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en)	2018-01-30	2020-08-28	Incyte Corp	Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
SMT202400306T1 (it)	2018-03-30	2024-09-16	Incyte Corp	Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
EP3836932A2 (de)	2018-08-17	2021-06-23	PTC Therapeutics, Inc.	Verfahren zur behandlung von bauchspeicheldrüsenkrebs
WO2020259683A1 (zh) *	2019-06-28	2020-12-30	成都赜灵生物医药科技有限公司	2，4-二取代嘧啶衍生物及其制备方法和用途
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
WO2022232259A1 (en) *	2021-04-28	2022-11-03	Cornell University	Soluble adenylyl cyclase (sac) inhibitors and uses thereof
CN115667251A (zh) *	2021-05-17	2023-01-31	株式会社沃若诺伊生物	杂芳基衍生物化合物、及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL112290A (en)	1994-01-12	1999-01-26	Novartis Ag	Transformed aryl and the troiryl pyrimidines and herbicides containing them
US5559137A (en) *	1994-05-16	1996-09-24	Smithkline Beecham Corp.	Compounds
AU754830C (en)	1997-05-22	2004-02-12	G.D. Searle Llc	Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) *	1997-05-22	2003-02-04	G.D. Searle & Company	Substituted pyrazoles as p38 kinase inhibitors
AU7966198A (en)	1997-06-13	1998-12-30	Smithkline Beecham Corporation	Novel pyrazole and pyrazoline substituted compounds
BR0013551A (pt)	1999-08-13	2003-06-17	Vertex Pharma	Inibidores de cinases n-terminal cjun (jnk) e outras cinases de proteìnas
GB9919778D0 (en)	1999-08-21	1999-10-27	Zeneca Ltd	Chemical compounds
AU3704101A (en)	2000-02-17	2001-08-27	Amgen Inc	Kinase inhibitors
WO2001062233A2 (en)	2000-02-25	2001-08-30	F. Hoffmann La Roche Ag	Adenosine receptor modulators
AU783981C (en)	2000-05-08	2007-05-03	Janssen Pharmaceutica N.V.	HIV replication inhibitors
ATE407132T1 (de)	2000-12-05	2008-09-15	Vertex Pharma	Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen
GB0129476D0 (en) *	2001-12-10	2002-01-30	Syngenta Participations Ag	Organic compounds

2002
- 2002-07-09 GB GBGB0215844.2A patent/GB0215844D0/en not_active Ceased
2003
- 2003-07-08 US US10/520,567 patent/US7691855B2/en not_active Expired - Fee Related
- 2003-07-08 BR BR0312573-4A patent/BR0312573A/pt not_active IP Right Cessation
- 2003-07-08 JP JP2004518751A patent/JP4478016B2/ja not_active Expired - Lifetime
- 2003-07-08 CA CA002491635A patent/CA2491635A1/en not_active Abandoned
- 2003-07-08 AT AT03762663T patent/ATE468332T1/de not_active IP Right Cessation
- 2003-07-08 CN CNB038163837A patent/CN1330643C/zh not_active Expired - Fee Related
- 2003-07-08 ES ES03762663T patent/ES2346427T3/es not_active Expired - Lifetime
- 2003-07-08 WO PCT/EP2003/007350 patent/WO2004005282A1/en not_active Ceased
- 2003-07-08 PT PT03762663T patent/PT1521749E/pt unknown
- 2003-07-08 EP EP03762663A patent/EP1521749B8/de not_active Expired - Lifetime
- 2003-07-08 AU AU2003249993A patent/AU2003249993A1/en not_active Abandoned
- 2003-07-08 DE DE60332629T patent/DE60332629D1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US7691855B2 (en)	2010-04-06
JP2006501183A (ja)	2006-01-12
EP1521749B1 (de)	2010-05-19
CA2491635A1 (en)	2004-01-15
EP1521749B8 (de)	2010-12-22
AU2003249993A1 (en)	2004-01-23
CN1330643C (zh)	2007-08-08
DE60332629D1 (de)	2010-07-01
WO2004005282A1 (en)	2004-01-15
JP4478016B2 (ja)	2010-06-09
GB0215844D0 (en)	2002-08-14
ES2346427T3 (es)	2010-10-15
EP1521749A1 (de)	2005-04-13
PT1521749E (pt)	2010-08-18
BR0312573A (pt)	2005-04-26
CN1668610A (zh)	2005-09-14
US20060106027A1 (en)	2006-05-18

Legal Events

Date	Code	Title	Description
2012-04-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE60332629D1 (de)	2010-07-01	Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin-2-yi)aminderivate
NO20062504L (no)	2006-07-21	Sammensetninger og doseringsformer for forbedret absorpsjon
SE0301700D0 (sv)	2003-06-10	Novel compounds
DE602006014990D1 (de)	2010-07-29	Intranasale verabreichung von schnell wirkendem insulin
GEP20125691B (en)	2012-11-26	Compounds and compositions as protein kinase inhibitors
GB0222514D0 (en)	2002-11-06	Organic compounds
ATE411022T1 (de)	2008-10-15	Pyridylpyrrol-derivate als wirksame kinase-hemmer
WO2005075425A3 (en)	2006-12-14	Substituted bisarylurea derivatives as kinase inhibitors
UA92000C2 (en)	2010-09-27	1-benzylindole-2-carboxamide derivatives
MY143795A (en)	2011-07-15	Tetrahydropyridoindole derivatives
CL2004000930A1 (es)	2005-03-18	Compuesto derivado de dihidroquinazolina de formula definida, util para el tratamiento y/o profilaxis de infecciones virales; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de medicamentos.
ATE384058T1 (de)	2008-02-15	Thiazolderivate
SE0401342D0 (sv)	2004-05-25	Therapeutic compounds
AU2020278236A8 (en)	2022-04-28	Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
UY29561A1 (es)	2006-12-29	Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones
MXPA03010054A (es)	2004-04-02	Composiciones que comprenden lopinavir y metodos para aumentar la biodisponibilidad de agentes farmaceuticos.
MX2007004248A (es)	2007-06-12	Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
CR8603A (es)	2007-06-08	Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
UA83832C2 (ru)	2008-08-26	Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и их применение
TW200612922A (en)	2006-05-01	Inhibitors of hsp90
SE0000303D0 (sv)	2000-01-31	Novel compounds
SE0203817D0 (sv)	2002-12-20	New composition
WO2004026319A3 (en)	2004-09-02	Pharmaceutical compositions increasing camp useful for the treatment of cancers
ATE496899T1 (de)	2011-02-15	Tetrahydro- und dihydrochinazolinone
DE602005014087D1 (de)	2009-06-04	7h-pyrrolopyrimidinderivate